Lexaria Bioscience Corp. (NASDAQ:LEXX) is set to release its quarterly earnings with an estimated EPS of -$0.16 and projected revenue of $137,000.
The company is conducting a human study on its DehydraTECH technology, showing potential in weight reduction and blood sugar level decrease.
Despite a negative P/E ratio of -3.60, LEXX’s financial metrics indicate a strong current ratio of 29.64 and a low debt-to-equity ratio of 0.013.

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company known for its innovative drug delivery technology, DehydraTECH. This technology enhances the delivery of bioactive compounds, improving their effectiveness. LEXX is set to release its quarterly earnings on April 8, 2025, with Wall Street estimating an earnings per share of -$0.16 and projected revenue of approximately $137,000.

LEXX is actively conducting a human study, GLP-1-H25-5, comparing oral DehydraTECH-liraglutide with injected Saxenda®-branded liraglutide. This study focuses on pharmacokinetics and safety, building on promising results from a previous rodent study. In that study, oral DehydraTECH-liraglutide achieved a 5.88% weight reduction and an 11.54% decrease in blood sugar levels.

Despite a negative price-to-earnings (P/E) ratio of -3.60, LEXX’s innovative research could potentially drive future growth. The company’s price-to-sales ratio of 55.81 indicates that investors are paying a premium for each dollar of sales, reflecting high expectations for its technology. The enterprise value to sales ratio of 39.82 further underscores the company’s valuation relative to its sales.

LEXX’s financial metrics reveal challenges, such as a negative enterprise value to operating cash flow ratio of -3.04 and an earnings yield of -27.79%. However, the company maintains a low debt-to-equity ratio of 0.013, indicating minimal reliance on debt. Additionally, a strong current ratio of 29.64 suggests a robust ability to cover short-term liabilities with short-term assets.